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Abstract
Background: B-type natriuretic peptide (BNP) levels during admission have been shown to have prognostic value
in the diagnosis of heart failure and further predict the in-hospital mortality of acute decompensated heart failure
(ADHF). This study describes the characteristics of BNP among hospitalized ADHF and elucidates its prognostic
value of in-hospital mortality in an Asian population.
Methods: We consecutively studied patients aged 20+ who were discharged with a diagnosis of ADHF from March
2013 to March 2014 in a tertiary hospital of northern Taiwan by reviewing medical records. Prognostic predictors of
mortality were assessed using Cox proportional hazard regression models. BNP > 100 pg/ml was used as the cut-off
for defining abnormally high BNP based on current clinical practice criteria.
Results: After implementation of our exclusion criteria, a total of 1,807 patients hospitalized with ADHF were studied.
Compared to those subjects with BNP ≤100 pg/ml, individuals with higher BNP tended to have more advanced age,
more clusters of the typical signs of heart failure (HF) (e.g., peripheral edema or lung rales) at presentation, lower
ejection fraction, lower hemoglobin levels, more disturbed biochemical data, worsened renal function, and twice the
risk for in-hospital mortality (15.2 vs 6.2 %, all p < 0.05). In a multivariate analysis, more advanced age, the presence of
rales, a worse New York Heart Association functional class, wider QRS duration, and abnormal BNP levels (>100 pg/ml)
were all associated with in-hospital mortality among admitted HF patients after accounting for clinical co-variates and
global ventricular ejection fraction (HR: 2.17, 95 % CI: 1.15–6.64, p = 0.024).
Conclusion: Abnormally high BNP levels in ADHF patients during admission were tightly linked to clinical features of
worse physical, functional, and clinical presentations, and further provided prognostic value for determining in-hospital
mortality among patients with ADHF in an Asian population.
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Background
Multiple epidemiologic studies have demonstrated that
advanced age [1], pulmonary basilar rales [2], dyspnea
[3], QRS duration [4] cardiomegaly [5], higher urea [6],
higher potassium [7, 8] lower sodium [9], higher B-type
Natriuretic Peptide (BNP) [10], and lower hemoglobin
[11] at presentation are all associated with in-hospital
mortality among patients with acute decompensated
heart failure (ADHF). BNP is among the most powerful
prognostic markers in all forms of clinical heart failure
(HF) [12]; it is recognized as a gold standard marker for
outcome prediction in HF [11, 13–15]. Clinically relevant
characteristics of Asian populations and the clinical prog-
nostic factors with hospitalized ADHF have not been fully
studied in a large observational cohort. The aims of this
study are to explore the clinical characteristics relevant to
abnormal BNP among unplanned hospitalized with ADHF
and to further evaluate determinants of in-hospital
mortality among ADHF in an Asian population.
Methods
This retrospective study of ADHF used electronic medical
records to investigate 1,807 consecutive patients aged 20+
who were hospitalized and discharged with a main clin-
ical diagnosis of HF from March 2013 to March 2014
in an urban tertiary teaching hospital in Taiwan. Data-
sets were collected as routine medical management and
hospitalization claims covered under the National Health
Insurance Bureau of Taiwan. Heart failure was defined by
using the European Society of Cardiology guidelines [16].
Hospitalization for heart failure was defined as unplanned
presentation at our emergency department of patients
receiving intravenous diuretic (e.g. loop diuretics, such
as furosemide) or vasodilator treatment of new or worsen-
ing HF requiring admission to our hospital [17, 18]. Defin-
ition of ADHF in our current work was made by new onset
or rapidly worsening HF signs and symptoms requiring ur-
gent and unplanned hospitalization [15, 19, 20]. As in pre-
vious hospitalized acute HF studies, BNP >100 pg/ml was
used as the cut-off for abnormally high BNP levels [21, 22].
Initial admission findings were mainly collected in the
emergency department. Clinical information including
cardiomegaly and data about left ventricular ejection
fraction (LVEF) were collected from echocardiography.
Pharmaceutical intravenous drugs administered at the
emergency department were abstracted. Medical histor-
ies of chronic heart failure (CHF), hypertension, diabetes,
coronary artery disease (CAD), chronic kidney disease
(CKD), dyslipidemia, stroke, and anemia were abstracted
as documented in electronic medical records. The main
exclusion criteria were end stage renal disease or initial
admission creatinine >3 mg/dl, acute coronary syndrome
(including myocardial infarction or unstable angina),
dialysis, terminal stage malignancy, liver cirrhosis, or life
expectancy less than 6 months.
Statistical analysis
Baseline characteristics of ADHF patients were expressed
as mean (standard deviation) for continuous variables and
frequency (percentage) for categorical variables. Stu-
dent T tests were used to test the differences between
groups for demographic characteristics and echocardiography-
derived measures or indices. Chi-square or the Fisher
exact test was used for comparisons of proportional
distributions of cardiovascular risk factors between
groups, as appropriate. The risk factors of all causes of
in-hospital mortality were determined using univariate
and multivariate Cox proportional hazard regression
models. The cumulative probability of in-hospital mortal-
ity by the BNP groups (>100 or ≤ 100 pg/ml) was graphic-
ally presented using the Kaplan Meier survival function
with comparison of cumulative events by the log-rank test.
The relationship between in-hospital mortality and
levels of BNP at admission was presented using locally
weighted smoothing regression scatterplots. The trend
of in-hospital mortality by quartiles (Q) of BNP were
Q1 < 260.5, Q2 260.5 to 617, Q3 618 to 1340, Q4 1341+
pg/ml was graphically presented using the Kaplan Meier
survival function with comparison of cumulative events
by chi-square. A two-sided p value < 0.05 was considered
as a statistically significant difference. All clinical variables
p < 0.10 in univariate Cox model were entered into multi-
variate analysis. All statistical analyses were performed
with Stata statistical software package (StataCorp. 2011.
Stata Statistical Software: Release 12. College Station, TX:
StataCorp LP.)
Results
Baseline demographic differences based on BNP level in
admitted ADHF individuals
A total of 1807 patients participated in our cohort
study: 927 were female (51.3 %), the mean age was
75.27 ± 14.12 years with ages ranging from 20+ to 103,
and average BNP levels were 1028.11 ± 1136.22 pg/ml.
The baseline characteristics stratified by BNP group are
presented in Table 1. More advanced age (76.3 vs
72.3 years, p = 0.003) was observed at admission in patients
with abnormally high levels of BNP (BNP > 100 pg/ml); no
gender distribution differences was observed (p = 0.63). Ini-
tial admission findings show that pulmonary basilar rales,
worse NYHA FC, peripheral edema, lower LVEF, higher
urine acid, higher urea, higher creatinine, lower glomerular
filtration rate (GFR), higher potassium, lower hemoglobin,
and a higher prevalence of medical histories of CKD and
A-fib were observed in those patients with BNP >100 pg/
ml versus patients with BNP ≤100 pg/ml. Length of
hospital stay and admission vital signs, including blood
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Age (year) 75.27 (14.12) 72.29 (14.53) 76.25 (14.07) 0.003
Gender
Female 927 (51.30 %) 65 (50.0 %) 876 (52.23 %) 0.630
Male 880 (48.69 %) 65 (50.0 %) 801 (47.77 %)
Mortality
Alive 1569 (86.83 %) 122 (93.85 %) 1421 (84.76 %) 0.005
Death 238 (13.17 %) 8 (6.15 %) 256 (15.24 %)
Stay in hospital (day) 12.05 (40.71) 14.34 (20.79) 14.33 (35.6) 0.985
Initial admission findings
Heart rate (beats/min) 90.27 (21.60) 91.83 (18.77) 92.81 (22.91) 0.584
SBP (mmHg) 135.87 (28.11) 135.59 (28.45) 136.33 (29.46) 0.786
DBP (mmHg) 74.26 (17.53) 73.26 (17.09) 74.41 (18.58) 0.501
Rales 599 (33.15 %) 36 (27.69 %) 467 (41.62 %) 0.002
PND 39 (2.15 %) 2 (1.54 %) 35 (3.12 %) 0.314
Orthopnea 138 (7.64 %) 7 (5.38 %) 122 (10.87 %) 0.051
NYHA FC (III-IV) 591 (32.70 %) 45 (34.62 %) 475 (42.34 %) 0.091
Peripheral edema 473 (26.18 %) 30 (23.08 %) 357 (31.82 %) 0.041
QRS duration (ms) 101.91 (24.92) 99.73 (23.01) 102.94 (25.44) 0.141
LVEF (%) 54.33 (13.70) 60.05 (9.68) 52.97 (14.09) <0.001
Cardiomegaly 667 (36.91 %) 56 (43.08 %) 516 (45.99 %) 0.528
Glucose (mg/dl) 168.35 (93.67) 172.16 (101.59) 178.56 (96.64) 0.480
HbA1c (%) 6.75 (1.74) 6.64 (1.68) 6.80 (1.75) 0.649
Total bilirubin (mg/dl) 1.31 (2.21) 0.93 (0.59) 1.38 (2.49) 0.072
GPT (u/l) 37.50 (70.82) 35.98 (63.76) 41.52 (80.69) 0.268
Urine acid (mg/dl) 7.32 (2.79) 6.62 (2.25) 7.72 (2.83) <0.001
Urea (mg/dl) 28.63 (17.92) 24.59 (17.02) 30.42 (18.00) <0.001
Creatinine (mg/dl) 1.46 (0.74) 1.28 (0.65) 1.54 (0.76) <0.001
GFR (ml/min/1.73 m2) 54.0 (30.90) 62.38 (31.14) 50.27 (28.89) <0.001
Potassium (meq/l) 4.08 (0.77) 3.89 (0.64) 4.09 (0.81) 0.001
Sodium (meq/l) 136.62 (6.14) 136.67 (5.65) 136.31 (6.42) 0.547
Troponin (ng/ml) 0.51 (3.62) 0.22 (1.68) 0.57 (4.06) 0.340
BNP (pg/ml) 1028.11 (1136.22) 46.81 (27.13) 1141.81 (1147.18) <0.001
Hemoglobin (g/dl) 11.40 (2.57) 12.29 (2.70) 11.25 (2.54) <0.001
Medical history (n, %)
CHF 1050 (58.11 %) 62 (47.69 %) 988 (54.63 %) 0.133
Hypertension 1100 (60.87 %) 81 (62.31 %) 1019 (59.36 %) 0.516
Diabetes 752 (41.62 %) 59 (45.38 %) 693 (42.25 %) 0.493
CAD 435 (24.07 %) 27 (20.77 %) 408 (22.37 %) 0.677
CKD 395 (21.86 %) 18 (13.85 %) 377 (23.89 %) 0.010
Dyslipidemia 376 (20.81 %) 30 (23.08 %) 346 (18.72 %) 0.232
Stroke 300 (16.60 %) 30 (23.08 %) 270 (17.91 %) 0.151
A-fib 396 (21.91 %) 13 (10.0 %) 383 (24.24 %) <0.001
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pressure and heart rates, showed no differences between
the BNP ≤ 100 and >100 pg/ml groups. Univariate and
multivariate analyses for clinical determinants of in-
hospital mortality are presented in Table 2.
Clinical predictors for in-hospital mortality
In a univariate Cox model, advanced age, presentation at
admission with pulmonary basilar rales, worse NYHA FC,
cardiomegaly, wider QRSD, higher total bilirubin, higher
potassium, lower sodium, abnormally high BNP and lower
hemoglobin were all associated with in-hospital mortality
among ADHF patients (all p < 0.05). Multivariate Cox
proportional hazard regression analysis was further
performed to determine the independent risk factors
associated with in-hospital mortality. After adjusting
for age, gender, rales, NYHA FC, QRSD, cardiomegaly,
total bilirubin, urine acid, urea, potassium, sodium, BNP,
and hemoglobin we found that more advanced age (HR:
1.02, 95 % CI: 1.01–1.03), presence of rales (HR: 1.50,
95 % CI: 1.07–2.11), worse NYHA FC (HR: 1.66, 95 % CI:
1.29–3.05), more widened QRS duration (HR: 1.01, 95 %
CI: 1.001–1.01) and admission with abnormally high BNP
(>100 pg/ml, HR: 2.17, 95 % CI: 1.15–6.64) were associ-
ated with in-hospital mortality among hospitalized
ADHF (all p < 0.05). Our patients in the higher BNP
group (BNP >100 pg/ml) had a graver prognosis than
their lower (BNP ≤100 pg/ml) counterparts. Kaplan-
Meier survival curves by BNP group are presented in
Fig. 1. (The log-rank test: χ2 = 6.78; p-value = 0.0092). A
local regression scatterplot smoothing of BNP levels and
in-hospital mortality risk is presented in Fig. 2—further
confirming BNP as a continuous clinical biomarker and a
predictor of in-hospital mortality. Kaplan-Meier survival
curves by quartiles (Q) of BNP were Q1 < 260.5 pg/ml, Q2
(260.5–617 pg/ml), Q3 (618–1340 pg/ml), Q4 ≥ 1341 are
presented in Fig. 3. Mortality rates in the BNP quartiles
were tested for trend of survival functions: Chi-square =
11.23; p-value = 0.0008. Higher BNP quartiles predicted
higher in-hospital mortality.
Discussion
Our cohort study revealed several findings: abnormally
high BNP levels, advanced age, pulmonary basilar rales,
worse NYHA FC, and a wider QRS duration were inde-
pendently associated with in-hospital mortality among
hospitalized ADHF patients. Admission BNP levels were
independently associated with in-hospital mortality. Krim
et al. [20] reported that in a large cohort in North America
with 92,072 participants from 264 hospitals, BNP levels at
admission in Asian patients averaged 1066 pg/ml; for
blacks 866 pg/ml; for whites 776 pg/ml; and for Hispanics
737 pg/ml. BNP levels at admission were 1028 pg/ml in
our study, which was comparable to previous studies. Pre-
vious data have proposed that BNP levels may vary with
genetic factors and that the higher BNP levels observed in
Asian populations may be related to higher rates of renal
insufficiency [20]. Indeed, Taiwan has the highest inci-
dence and prevalence rates of end stage renal disease and
a high prevalence of CKD [23], making renal insufficiency
a likely cause of the comparatively high average BNP levels
in our cohort.
From the large observational database ADHERE (Acute
Decompensated Heart Failure National Registry)—a regis-
try contained data on patients hospitalized with acute de-
compensated HF from 191 hospitals across United States
of America—Fonarow et al. [22] reported that BNP levels
at admission independently predicted mortality in ADHF
patients hospitalized with reduced and preserved systolic
function. To the best of our knowledge, data regarding the
clinical presentation and in-hospital prognostic informa-
tion using prior BNP in an admitted HF cohort remained
largely unknown in large Asian populations. Our analysis
of a relatively large group of HF hospitalizations con-
firmed that admission BNP levels can be a reliable and ac-
countable predictor of the risk of in-hospital mortality
among hospitalized ADHF. Previously, many other publi-
cations reported that BNP contributed independently to
the risk prediction of in-hospital mortality. Our analysis
shows that admission levels of BNP give prognostic infor-
mation about patients hospitalized for ADHF. Moreover,
Table 1 Baseline characteristics categorized by BNP group (Continued)
Anemia 167 (9.24 %) 9 (6.92 %) 158 (9.98 %) 0.264
Hepatitis 38 (2.10 %) 4 (3.08 %) 34 (2.23 %) 0.543
Medications (n, %)
Diuretics 1432 (79.26 %) 85 (65.38 %) 1347 (80.32 %) <0.001
Nitrates 844 (46.7 %) 91 (70.00 %) 753 (44.90 %) <0.001
Digoxin 87 (4.86 %) 4 (3.08 %) 83 (4.95 %) 0.337
Beta blocker 72 (3.98 %) 0 (0 %) 72 (4.29 %) 0.016
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, PND paroxysmal nocturnal dyspnea, NYHA FC New York Heart Association functional class,
LVEF left ventricular ejection fraction, HbA1c glycated hemoglobin, GPT glutamate pyruvate transaminase, GFR glomerular filtration rate, BNP B-type natriuretic
peptide, CHF chronic heart failure, CAD coronary artery disease, CKD chronic kidney disease, A-fib atrial fibrillation
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it is the first to report in an Asian population. BNP has
been globally used to assist clinical decision-making and
to critically appraise patients with HF. However, interpret-
ation of BNP measurements also depends on many factors
including obesity, CKD, the status of congestion or decon-
gestion, specific treatments, and race/ethnicity among
hospitalized ADHF patients [12]. Similar to prior find-
ings, our work showed that several key clinical co-
variates, including worse NYHA FC, presence of rales,
wider QRS duration, as well as abnormally high BNP
(set at 100 pg/ml) remained as independent prognosti-
cators of in-hospital mortality.
Table 2 Predictors of in-hospital mortality (univariate and multivariate analysis)
Univariate Multivariate
Variables HR [95 % C.I. for HR] P-value HR [95 % C.I. for HR] P-value
Age (year) 1.692 (1.152, 2.486) 0.007 1.020 (1.01, 1.03) 0.007
Gender (Male/Female) 1.102 (0.849, 1.430) 0.464
Heart rate (beats/min) 1.004 (0.999, 1.009) 0.152
SBP (mmHg) 0.997 (0.993, 1.001) 0.177
DBP (mmHg) 0.995 (0.988, 1.003) 0.223
Rales 1.709 (1.317, 2.218) <0.001 1.500 (1.065, 2.114) 0.02
PND 0.526 (0.131, 2.121) 0.367
Orthopnea 0.645 (0.359, 1.160) 0.143
NYHA FC (III-IV) 1.980 (1.436, 2.433) <0.001 1.662 (1.288, 3.052) 0.002
Peripheral edema 0.824 (0.595, 1.141) 0.243
QRS duration (ms) 1.007 (1.002, 1.012) 0.007 1.010 (1.001, 1.01) 0.023
LVEF (%) 1.002 (0.988, 1.015) 0.812
Cardiomegaly 1.505 (1.151, 1.969) 0.003 0.945 (0.617, 1.448) 0.796
Glucose (mg/dl) 0.999 (0.998, 1.001) 0.359
HbA1c (%) 0.801 (0.627, 1.023) 0.076
Total bilirubin (mg/dl) 1.052 (1.009, 1.098) 0.018 1.037 (0.978, 1.099) 0.222
GPT (u/l) 1.000 (0.998, 1.001) 0.618
Urine acid (mg/dl) 1.046 (0.994, 1.101) 0.081
Creatinine (mg/dl) 1.106 (0.939, 1.304) 0.227
GFR (ml/min/1.73 m2) 1.000 (0.996, 1.005) 0.833
Potassium (meq/l) 1.262 (1.109, 1.436) <0.001 1.125 (0.939, 1.347) 0.202
Sodium (meq/l) 0.978 (0.961, 0.995) 0.010 1.000 (0.973, 1.027) 0.979
Troponin (ng/ml) 1.004 (0.963, 1.046) 0.864
BNP (>100/≤100) 2.486 (1.218, 5.071) 0.012 2.170 (1.145, 6.640) 0.024
Hemoglobin (g/dl) 0.904 (0.856, 0.954) <0.001 0.971 (0.901, 1.046) 0.433
CHF 0.779 (0.600, 1.012) 0.161
Hypertension 0.672 (0.517, 0.872) 0.303
Diabetes 0.770 (0.587, 1.009) 0.158
CAD 0.801 (0.558, 1.149) 0.228
CKD 0.565 (0.380, 0.839) 0.505
Dyslipidemia 1.321 (0.967, 1.806) 0.180
Stroke 0.942 (0.673, 1.317) 0.726
A-fib 0.455 (0.306, 0.676) 0.101
Anemia 0.655 (0.394, 1.089) 0.103
Hepatitis 1.351 (0.666, 2.739) 0.404
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, PND paroxysmal nocturnal dyspnea, NYHA FC New York Heart Association functional class,
LVEF left ventricular ejection fraction, HbA1c glycated hemoglobin, GPT glutamate pyruvate transaminase, GFR glomerular filtration rate, BNP B-type natriuretic
peptide, CHF chronic heart failure, CAD coronary artery disease, CKD chronic kidney disease, A-fib atrial fibrillation
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Careful clinical evaluation/reasoning and interpretation
of laboratory results in the correct context will always add
to laboratory tests alone in patients with complex syn-
drome of HF. Clinical decision-making involves many
factors, including understanding scientific evidence, ex-
perience, and the patient’s profile. Even if levels of BNP
are easily available, yield quick results, and are widely
used, they still do not contribute explicit guidance re-
garding specific HF therapies. Rapid and early patient
identification may aid faster progressive therapies that
improve a patient’s symptoms and enable an estimate of
the combined end point of death and failure to achieve a
favorable health status [24]. Our analyses in this observa-
tional cohort suggest rales and worse NYHA FC (two con-
gestive signs on physical assessment) were independently
associated with in-hospital mortality. Worse functional
class has been the most common sign and symptom of
heart failure causing patients to seek medical treatment at
emergency departments. Early dyspnea relief had been
demonstrated to be associated in reduced mortality
Dyspnea is an important marker of congestion and a tar-
get for treatment. However, there is no validated method
of measuring dyspnea in HF patients [25]. A post-hoc ana-
lysis of the AF-CHF (Atrial Fibrillation and Chronic Heart
Failure) found that rales was associated with mortality
among other congestive signs including peripheral edema,
jugular venous distension, and a third sound [2]. Our
study and the AF-CHF Trial continue to show that
congestive signs on physical assessment have important
prognostic value in HF patients. A retrospective analysis
of the CIBIS-II (Cardiac Insufficiency Bisoprolol Study –
II) in 2647 patients with NYHA functional class III to IV
symptoms, found that congestive signs of jugular venous
distension and peripheral edema were associated with HF
in-hospital mortality [26]. Importantly, rale as a congestive
sign on physical assessment was not evaluated [2]. Further,
wide QRS duration had also recently been proved to be a
key prognosticator in HF survival and hospitalization [27].
In line with these prior reports, our study demonstrated
that admission levels of BNP, advanced age, worse NYHA
FC, wider QRS duration and pulmonary rales were the
strongest risk factors for mortality among unplanned hos-
pitalized with ADHF. These analyses suggest that conven-
tional physical assessments in this modern era continue to
provide important prognostic value over the more routine
clinical parameters of electrocardiography and echocardi-
ography, especially LVEF [2].
There were a total of 7 % admitted HF subjects who
presented with BNP levels < 100 pg/ml in our current
study. Fonarow et al. reported a 3.3 % prevalence of HF
subjects with BNP levels <100 pg/ml from ADHERE
(Acute Decompensated Heart Failure National Registry)
from 48,629 hospitalizations [22]. A previous study re-
ported that BNP levels provided the accurate diagnosis
of 81.1 % (sensitivity of 90 % and specificity of 74 %) at a
cutoff of >100 pg/ml among congestive heart failure pa-
tients presenting at the emergency department [21]. In
Fig. 1 Kaplan-Meier survival curves by BNP group. (The log-rank test:
χ2 = 6.78; p-value = 0.0092)
Fig. 2 Scatterplot Smoother of admission BNP levels and
in-hospital mortality
Fig. 3 Kaplan-Meier survival curves for BNP quartiles. Test for trend
of survival functions: Chi-square = 11.14; P = 0.0008
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our study and a report from ADHERE [22], patients in
the higher BNP quartiles had a higher trend for mortality.
Thus admission levels of BNP allow the acquisition of
expedited prognostic information regarding in-hospital
mortality for hospitalized ADHF patients. Based on our
findings, rapid and early recognition of several specific
risk factors may benefit a subgroup of patients for whom
aggressive optimization of drug or device therapies could
improve their outcomes and further provide possible
beneficial interventions to improve their in-hospital sur-
vival during admission.
Limitations
The results of this observational study should be inter-
preted in the context of several limitations. This is a single
center study with retrospective manner and may not rep-
resent the general population. Although consecutiveness
of enrollment was rigidly recommended, a hospitalized
patient census was not checked or available. Therefore, we
cannot prove the consecutiveness of patient enrollment.
The accuracy and completeness of collected dataset de-
pends on the original documenters. Patients were mainly
recruited from the cardiology and pulmonary departments,
and thus might not represent the general population. We
did not report oral medications at admission. The dataset
of home regimen medications was not complete or
unavailable.
Conclusion
Admission BNP levels remained a prognostic value for
determining in-hospital mortality among patients with
unplanned hospitalization with ADHF in our Asian popu-
lation. The prognostic value of BNP in such a patient
population was also shown to be independent of other
clinical or lab data, including echocardiography. Routine
clinical implementation of biomarkers for any admitted
HF patient has therefore been proposed to better under-
stand the pathophysiological mechanisms and to offer not
only a more accurate prediction of the specific patient
subgroup at higher risk for unfavorable in-hospital events
but also facilitate the introduction of effective therapy, if
needed, in a timely fashion.
Key messages
1. Admission BNP levels provided prognostic value for
determining in-hospital mortality among patients with
unplanned hospitalization with ADHF in our Asian
population.
2. Congestive signs of pulmonary rales and dyspnea on
the physical assessment continue to provide prognostic
value.
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